After being one of the protagonists in the vaccine race against Covid-19, the biotechnology company Moderna will develop new vaccines. However, the new vaccines, in addition to offering protection against SARS-Cov V-2, should also fight influenza and respiratory syncytial virus (RSV). Understand more about the study.
Read more: HIV Vaccine: See what is currently known.
see more
Confirmed: Samsung really is producing foldable screens for…
China conducts experiments with zebrafish on the space station…
Moderna's new project aims to be broader in terms of protection against respiratory diseases. According to the company's announcement, it was noticed that there is an aging trend in the United States, and this population is more vulnerable to these diseases. So any of the respiratory illnesses, even the common flu, can trigger a public health crisis.
To avoid this situation, Moderna intends to launch a new vaccine that will work as a kind of three in one. That is, while offering protection against Covid-19, the vaccine will also act against influenza and VSR. Similar to the vaccination scheme that was experienced in pandemic times, this new immunization would also require a booster dose. Until then, the need for only one booster dose one year after the first one has been discussed.
In addition to the combinatorial vaccine, Moderna has also started work to combat the common cold. For this, the proposed vaccine must combat the four endemic human coronaviruses, which are HCoV229E, HCoVNL63, HCoV-OC43 and HCoV-HKU1. According to studies, protection against these viruses would be enough to block some of the causes of the common cold, but not all.
In fact, the four endemic coronaviruses we mentioned correspond to one in ten cases of the common cold, or one in three respiratory infections. This information was provided by Mark Cameron, who is an associate professor in the department of population and health at Case Western Reserve University School of Medicine. Cameron also warns of the need to take advantage of the scientific development of vaccines during the Covid-19 pandemic to follow the path of manufacturing immunizers.
